Expand OCGN Menu
OCGN MENU

OCGN Latest Press Releases

-- January 27, 2025 --

Ocugen, Inc. Announces Investigational New Drug Application in Effect After Review by FDA to Initiate Phase 1 Clinical Trial Evaluating First-in-Class OCU500 Inhaled Vaccine Candidate for COVID-19 Globe Newswire 6:30 AM

-- January 16, 2025 --

Ocugen, Inc. Announces First Patient Dosed in Phase 1 Clinical Trial of OCU200-a Novel Integrin-Targeting Biologic for Diabetic Macular Edema Globe Newswire 7:30 AM

-- January 13, 2025 --

Ocugen, Inc. Announces Positive 2-Year Data Across Multiple Mutations from Phase 1/2 Clinical Trial of OCU400 -A Novel Modifier Gene Therapy for Retinitis Pigmentosa Globe Newswire 6:30 AM

-- December 19, 2024 --

Data and Safety Monitoring Board Reviews Interim Safety Data of Phase 2 Subjects of OCU410 ArMaDa Clinical Trial for Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration Globe Newswire 6:38 AM

-- December 11, 2024 --

Ocugen CEO to Present at Oppenheimer Movers in Rare Disease Summit Globe Newswire 7:02 AM

-- November 27, 2024 --

Ocugen CEO to Present at NobleCon20 Noble Capital Markets' 20th Annual Emerging Growth Equity Conference Globe Newswire 7:09 AM

-- November 20, 2024 --

Ocugen Announces European Medicines Agency Grants Orphan Medicinal Product Designation for Modifier Gene Therapy Candidate OCU410ST for Treatment of ABCA4-Associated Retinopathies including Stargardt Disease Globe Newswire 7:30 AM

-- November 19, 2024 --

Ocugen Announces Compelling Preliminary Data for OCU410-a Single Dose Novel Modifier Gene Therapy to Treat Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration Globe Newswire 7:02 AM

-- November 8, 2024 --

Ocugen Provides Business Update with Third Quarter 2024 Financial Results Globe Newswire 6:45 AM

-- November 7, 2024 --

Ocugen Secures $30 Million in Debt Funding Globe Newswire 6:30 AM

-- October 28, 2024 --

Ocugen Clinical Showcase Highlighting Progress in Retinal Gene Therapy Clinical Trials in New York City on Tuesday, November 12, 2024 Globe Newswire 6:30 AM

-- October 22, 2024 --

Data and Safety Monitoring Board Approves Initiation of Phase 2 of OCU410ST GARDian Clinical Trial for Stargardt Disease Globe Newswire 7:02 AM

-- October 17, 2024 --

Ocugen to Host Conference Call on Friday, November 8 at 8:30 A.M. ET to Discuss Business Updates and Third Quarter 2024 Financial Results Globe Newswire 7:30 AM

-- October 10, 2024 --

Ocugen to Participate in 2024 Maxim Healthcare Virtual Summit Globe Newswire 7:00 AM

-- October 9, 2024 --

Ocugen, Inc. Announces Removal of Clinical Hold on Investigational New Drug Application for OCU200 Phase 1 Clinical Trial Globe Newswire 6:30 AM

-- October 2, 2024 --

Ocugen to Present at the 2024 Cell & Gene Meeting on the Mesa Globe Newswire 6:30 AM

-- September 24, 2024 --

Ocugen to Participate in a Fireside Chat at Chardan's 8th Annual Genetic Medicines Conference Globe Newswire 7:30 AM

-- September 17, 2024 --

Kaskela Law LLC Announces Shareholder Investigation of Ocugen, Inc. (NASDAQ: OCGN) and Encourages Investors to Contact the Firm Business Wire 8:00 AM

-- September 9, 2024 --

Ocugen Chairman, CEO & Co-founder, Dr. Shankar Musunuri, to Speak During U.S.-India Initiative on Critical and Emerging Technology Workshop Globe Newswire 6:30 AM

-- September 5, 2024 --

Ocugen CSO to Participate in 5th Annual Gene Therapy for Ophthalmic Disorders Summit Globe Newswire 7:00 AM

-- September 3, 2024 --

Ocugen to Participate in a Fireside Chat at the H.C. Wainwright 26th Annual Global Investment Conference Globe Newswire 7:30 AM

-- August 28, 2024 --

Ocugen Announces Completion of Dosing in Subjects with Stargardt Disease in High Dose Cohort of Phase 1/2 GARDian Clinical Trial of OCU410ST-A Modifier Gene Therapy Globe Newswire 6:30 AM